UTA.00211.LQT1	
    			    			
                TAUi007-B            
            
        General
Cell Line | 
					|
| hPSCreg name | TAUi007-B | 
| Cite as: | TAUi007-B (RRID:CVCL_RN18) | 
| Alternative name(s) | 
									 
	UTA.00211.LQT1	 
							 | 
						
| Cell line type | Human induced pluripotent stem cell (hiPSC) | 
| Similar lines | 
							 TAUi007-A (UTA.00208.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi006-A (UTA.00102.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 TAUi006-B (UTA.00118.LQT1) Donor's gene variants: KCNQ1 – potassium voltage-gated channel subfamily Q member 1 Donor diseases: Long QT Syndrome 1 LUMCi039-A (LQT1-1781G/A hiPSC, LUMC0021iKCNQ-30) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Long QT Syndrome 1 UKKi034-A (NP0079-A, NP0079-7B) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Congenital long QT syndrome UKKi034-B (NP0079-B, NP0079-15B) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Congenital long QT syndrome UKKi034-C (NP0079-C, NP0079-16H) Donor's gene variants: KCNQ1, KCNQ1 Donor diseases: Congenital long QT syndrome LUMCi027-A (LUMC0153iPKP03) Donor's gene variants: PKP2 Donor diseases: arrhythmogenic right ventricular dysplasia 9 TAUi005-A (UTA.14511.CPVT) Donor's gene variants: RYR2 Donor diseases: Catecholaminergic polymorphic ventricular tachycardia  | 
					
| Last update | 19th April 2022 | 
| User feedback | |
Provider | 
					|
| Generator | Tampere University (TAU) | 
| Derivation country | Finland | 
External Databases | 
						|
| BioSamples | SAMEA8549178 | 
| Cellosaurus | CVCL_RN18 | 
| Wikidata | Q54992203 | 
							    
							General Information | 
					|
| Publications | 
  | 
    						
| Projects | |
| * Is the cell line readily obtainable for third parties? | 
                                     Yes                                                                                 Cell line can only be used in: ERC StG-project of Sara Liin 
                                                                                    Research use: allowed 
                                                                                    Clinical use: not allowed 
                                                                                    Commercial use: allowed 
                                                                         | 
                            
Donor Information
General Donor Information | 
					|
| Sex | female | 
Phenotype and Disease related information (Donor) | 
					|
| Diseases | A disease was diagnosed.
																	 | 
					
Karyotyping (Donor) | 
						|
| Has the donor karyotype been analysed? | 
								 No 								
															 | 
						
Other Genotyping (Donor) | 
						|
| Is there genome-wide genotyping or functional data available? | 
								 No 								
															 | 
						
Donor Relations | 
							|
| Other cell lines of this donor | |
External Databases (Donor) | 
						|
| BioSamples | SAMEA8549179 | 
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes | 
| Was the consent voluntarily given? | Yes | 
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes | 
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes | 
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes | 
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised | 
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes | 
| * Does consent pertain to a specific research project? | No | 
| Does consent permit unforeseen future research, without further consent? | Yes | 
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No | 
| Does consent expressly prevent development of commercial products? | No | 
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No | 
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No | 
Does consent permit research by | |
| an academic institution? | Yes | 
| a public organisation? | Yes | 
| a non-profit company? | Yes | 
| a for-profit corporation? | Yes | 
| How may genetic information associated with the cell line be accessed? | No information | 
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes | 
| Name of accrediting authority involved? | Ethics Committee of Pirkanmaa Hospital District | 
| Approval number | R08070 | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | No | 
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General | 
						|
| Source cell type | |
| Collected in | 2008 | 
Reprogramming method | 
						|
| Vector type | Integrating | 
| Vector | Virus (Retrovirus) | 
| Genes | |
| Is the used vector excisable? | 
										 Unknown 									 | 
								
| Absence of reprogramming vector(s)? | 
										 Unknown 									 | 
								
| Reprogramming vectors silenced? | |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming | 
						|
| Type of used vector free reprogramming factor(s) | 
								 
	None	 
							 | 
						
Other | 
						|
| Selection criteria for clones | Morphology | 
| Derived under xeno-free conditions | 
								 No 							 | 
						
| Derived under GMP? | 
								 No 							 | 
						
| Available as clinical grade? | 
								 No 							 | 
						
Culture Conditions
| Surface coating | Gelatin | ||||||||||||||||||
| Feeder cells | 
																								CF-1 MEF MITC Cellfinder Ont Id: CELDA_00007731  | 
						||||||||||||||||||
| Passage method | 
								Enzymatically
								
																			 
											Collagenase										 
																	
								
							 | 
						||||||||||||||||||
| CO2 Concentration | 5 % | ||||||||||||||||||
| Medium | 
								Other medium:		 
			Base medium: KO-DMEM			 
				
				Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements 
				
  | 
						||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No  | 
					||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No  | 
					||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No  | 
					
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| NANOG | 
											 Yes 						                 | 
																                
						                |||||
| SOX2 | 
											 Yes 						                 | 
																                
						                |||||
| POU5F1 (OCT-4) | 
											 Yes 						                 | 
																                
						                |||||
| ZFP42 (REX-1) | 
											 Yes 						                 | 
																                
						                
Genotyping
Karyotyping (Cell Line) | 
					|
| Has the cell line karyotype been analysed? | 
								 Yes 								
																	
															 | 
						
Other Genotyping (Cell Line) | 
					|

Login to share your feedback, experiences or results with the research community.